

GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069
(CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - corporaterelations@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs. in Lakhs except EPS)

Statement of Audited Financial Results for the Quarter and Year Ended March 31, 2022

1]	Sr. No.	Particulars	Quarter Ended			Year Ended	
			31-Mar-22	31-Dec-21	31-Mar-21	31-Mar-22	31-Mar-21
			Audited	Unaudited	Audited	Audited	Audited
	1	Income					
	a	Revenue from operations	16,219.31	17,206.54	13,192.92	77,915.56	48,769.87
	b	Other income	4.07	153.03	65.57	310.42	373.29
		Total Income	16,223.38	17,359.57	13,258.49	78,225.98	49,143.16
	2	Expenses					
	a	Cost of materials consumed	7,732.65	7,504.09	4,957.41	35,393.40	21,345.17
	b	Purchase of stock-in-trade	1,218.54	1,106.02	760.52	7,741.84	2,255.25
	c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,803.43)	175.13	820.32	(1,938.86)	1,428.79
	d	Employee benefits expense	1,930.99	2,070.70	1,725.91	8,561.18	6,621.80
	e	Finance cost	105.65	103.22	287.20	484.68	1,363.33
	f	Depreciation and amortisation expense	432.71	448.41	448.23	1,713.38	1,630.76
	g	Other expenses	3,988.64	3,078.82	2,554.05	13,586.53	8,726.91
		Total Expenses	13,605.75	14,486.39	11,553.64	65,542.15	43,372.01
	3	Total Profit before exceptional items and tax (1-2)	2,617.63	2,873.18	1,704.85	12,683.83	5,771.15
	4	Exceptional items	-	-	-	-	-
	5	Total Profit Before Tax	2,617.63	2,873.18	1,704.85	12,683.83	5,771.15
	6	Tax expense					
		Current tax	665.00	727.00	805.01	3,215.00	1,719.82
		Deferred tax	(73.79)	42.92	187.31	(115.18)	201.14
		Short/(Excess) tax provision of earlier years	-	-	(574.51)	-	(572.97)
		Total Tax Expenses	591.21	769.92	417.81	3,099.82	1,347.99
	7	Net Profit for the period from continuing operations	2,026.42	2,103.26	1,287.04	9,584.01	4,423.16
	8	Total Profit for period	2,026.42	2,103.26	1,287.04	9,584.01	4,423.16
	9	Other Comprehensive Income (OCI)					
		Items that will not be reclassified to Profit/(Loss)	(58.88)	-	38.51	(58.88)	38.51
		Less: Income tax relating to items that will not be reclassified to Profit/(Loss)	14.82	-	(11.41)	14.82	(11.41)
		Other Comprehensive Income/(Loss) (net of taxes)	(44.06)	-	27.10	(44.06)	27.10
	10	Total Comprehensive Income	1,982.36	2,103.26	1,314.14	9,539.95	4,450.26
	11	Reserves				25,942.35	16,374.20
	12	Details of Equity Share Capital					
		Paid-up equity share capital	969.45	969.45	969.45	969.45	969.45
		Face value of equity share capital (₹)	1.00	1.00	1.00	1.00	1.00
	13	Earning per equity share					
	i	Basic earnings per share from continuing and discontinued operations	2.09	2.17	1.33	9.89	4.56
	ii	Diluted earnings per share from continuing and discontinued operations	2.09	2.17	1.33	9.89	4.56



[Handwritten signature]

For identification purpose only

GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069
(CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - corporaterelations@guficbio.com, Ph-022 67261000 Fax - 022 67261068

(Rs. in Lakhs)

Statement of Assets and Liabilities			
2]	Particulars	As at	As at
		March 31, 2022	March 31, 2021
		(Audited)	(Audited)
	ASSETS		
	Non-Current Assets		
	Property, plant and equipment	11,175.64	9,376.41
	Intangible assets	61.02	44.51
	Capital work-in-progress	4,087.42	1,340.05
	Right of use assets	280.03	576.07
	Financial Assets		
	i. Investments	0.75	0.75
	ii. Loans	24.07	29.04
	iii. Other financial assets	908.49	1,129.68
	Deferred tax assets (Net)	-	-
	Other non-current assets	3,527.35	651.31
	Total Non-Current Assets	20,064.77	13,147.82
	Current Assets		
	Inventories	11,556.69	9,440.46
	Financial Assets		
	i. Investments	-	-
	ii. Trade receivables	15,155.29	12,450.07
	iii. Cash and cash equivalent	1,160.80	620.14
	iv. Bank balances	1,496.31	697.65
	v. Loans	38.26	25.32
	Other current assets	2,668.05	2,824.64
	Current tax asset (net)	-	-
	Total Current Assets	32,075.40	26,058.28
	TOTAL ASSETS	52,140.17	39,206.10
	EQUITY AND LIABILITIES		
	Equity		
	Equity share capital	969.45	969.45
	Other equity	25,942.35	16,374.20
	Total Equity	26,911.80	17,343.65
	Liabilities		
	Non-Current Liabilities		
	Financial Liabilities		
	i. Borrowings	4,739.73	3,542.65
	ii. Other Financial Liabilities	499.75	499.75
	iii. Lease liability	32.88	282.24
	Provisions	1,238.86	1,022.62
	Deferred tax liabilities (net)	18.95	148.95
	Total Non- Current Liabilities	6,530.17	5,496.21
	Current Liabilities		
	Financial Liabilities		
	i. Borrowings	659.92	1,632.43
	ii. Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	698.98	387.00
	Total outstanding dues of other than micro enterprises and small enterprises	13,396.14	10,915.86
	iii. Other financial liabilities	1,868.23	1,533.54
	iv. Lease liability	281.65	336.61
	Provisions	487.15	456.52
	Other current liabilities	1,238.66	946.08
	Current tax liabilities (Net)	67.48	158.20
	Total Current Liabilities	18,698.21	16,366.24
	Total Liabilities	25,228.37	21,862.45
	TOTAL EQUITY AND LIABILITIES	52,140.17	39,206.10



Gufic Biosciences Limited

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069
(CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - corporaterelations@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs. in Lakhs)

Statement of Cash Flow


3]	Particulars	For the year ended	For the year ended
		March 31, 2022	March 31, 2021
		(Audited)	(Audited)
	A. Cash flows from operating activities		
	Profit for the year	9,584.01	4423.17
	Adjustments for:		
	Income tax expense recognised in profit or loss	3,099.82	1347.99
	Depreciation	1,713.38	1630.76
	Dividend	(0.05)	-
	Interest income on fixed deposits with banks	(78.17)	(57.01)
	Interest income on financial assets carried at amortised cost	(109.74)	(88.04)
	Interest costs on financial liabilities measured at amortised cost	484.68	1363.33
	Non current security deposits at amortised cost	88.00	73.64
	Profit on sale of fixed asset	(6.84)	3.74
	Sundry credit balances written back	(4.79)	152.33
	Operating profit before movements in the working capital	14,770.30	8849.91
	Movements in working capital:		
	(Increase)/decrease in trade and other receivables	(2,319.31)	(1899.00)
	(Increase)/decrease in inventories	(2,116.23)	2805.68
	Increase/ (Decrease) in trade and other payables	3,415.39	90.19
		(1,020.15)	996.87
	Cash generated from operations	13,750.15	9846.78
	Income taxes paid	(3,305.72)	(940.29)
	Net cash generated by operating activities (A)	10,444.43	8906.49
	B. Cash flows from investing activities		
	Purchase of property, plant and equipments including capital advances and purchase of intangibles	(8,880.16)	(1,417.78)
	Sale of property, plant and equipments	6.84	(3.56)
	Other dividend received	0.05	-
	Balance in earmarked accounts	(777.40)	514.97
	Interest income on fixed deposits with banks	56.90	55.68
	Net cash used in investing activities (B)	(9,593.77)	(850.69)
	C. Cash flows from financing activities		
	Proceeds / (Repayment) from current borrowings	(972.51)	(7677.90)
	Proceeds / (Repayment) from non current borrowings	1,561.85	1538.68
	Processing fees paid	(22.00)	-
	Payment on lease liabilities	(304.33)	(344.44)
	Payment for interest if lease liabilities	(62.65)	(93.90)
	Dividends paid on equity shares	(92.11)	(36.29)
	Interest paid	(418.25)	(1247.95)
	Net cash generated from financing activities (C)	(310.00)	(7,861.80)
	Net increase in cash and cash equivalents (A + B + C)	540.66	194.00
	Cash and cash equivalents at the beginning of the financial year	620.14	426.14
	Cash and cash equivalents at the end of the financial year	1,160.80	620.14



4] Notes:

1. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder.
2. The above results for the quarter and year ended March 31, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 20, 2022. The Statutory Auditors have carried out audit of the results for quarter and year ended March 31, 2022.
3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals.
4. The Board of Directors at its meeting held on May 20, 2022 has recommended a final dividend of ₹ 0.10 (Rupees Zero Point Ten only) per equity share i.e., @ 10% on the face value of ₹ 1/- each, for the financial year 2021-22, subject to the approval of the shareholders at the ensuing Annual General Meeting.
5. The figures for the quarter ended March 31, 2022 and March 31, 2021 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended December 31, 2021 and December 31, 2020 respectively, which were subjected to limited review.
6. Previous year/quarters figures have been regrouped/reclassified, wherever necessary.

FOR GUFIC BIOSCIENCES LIMITED


PRANAV J. CHOKSI
CEO & WHOLE TIME DIRECTOR
DIN : 00001731



PLACE : MUMBAI
DATE : 20/05/2022



For identification purpose only.